Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome

Int J Gynaecol Obstet. 2007 Dec;99(3):236-41. doi: 10.1016/j.ijgo.2007.05.045. Epub 2007 Sep 25.

Abstract

Objective: To assess plasmapheresis with low dose prednisone on obstetric and neonatal outcomes among unsuccessfully treated pregnant women with documented antiphospholipid syndrome (APS).

Methods: Eighteen pregnant women received prednisone (10 mg/day) and plasmapheresis at 7.08+/-0.6 weeks of gestation, for 3 sessions per week, until lupus anticoagulant activity suppressed and IgG anticardiolipin lowered. Serial pulsatility indexes (PI) of umbilical and uterine arteries were performed.

Results: The live birth rate was 100%; mild pre-eclampsia 5.5%; preterm deliveries 22.22%; intrauterine growth restriction 11.11%; thrombocytopenia 5.5%; oligohydramnios and fetal distress 16.6%. There were no perinatal deaths, thrombotic events or lupus flare. Uterine artery PI was reduced and umbilical artery PI was >95th percentile.

Conclusion: Plasmapheresis and low dose prednisone were associated with a low rate of obstetric and neonatal complications. Plasmapheresis may be used to treat pregnant women with documented APS when first lines (aspirin and/or heparin) fail to prevent pregnancy loss.

Publication types

  • Clinical Trial

MeSH terms

  • Abortion, Habitual / therapy*
  • Adult
  • Anti-Inflammatory Agents / therapeutic use
  • Antiphospholipid Syndrome / therapy*
  • Female
  • Humans
  • Live Birth
  • Pilot Projects
  • Plasmapheresis*
  • Prednisone / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Hematologic / therapy*
  • Pulsatile Flow

Substances

  • Anti-Inflammatory Agents
  • Prednisone